Literature DB >> 21457715

Chelerythrine perturbs lamellar actomyosin filaments by selective inhibition of myotonic dystrophy kinase-related Cdc42-binding kinase.

Ivan Tan1, Jesyin Lai, Jeffery Yong, Sam F Y Li, Thomas Leung.   

Abstract

Cell movement requires forces generated by non-muscle myosin II (NM II) for coordinated protrusion and retraction. The Cdc42/Rac effector MRCK regulates a specific actomyosin network in the lamella essential for cell protrusion and migration. Together with the Rho effector ROK required for cell rear retraction, they cooperatively regulate cell motility and tumour cell invasion. Despite the increasing importance of ROK inhibitors for both experimental and clinical purposes, there is a lack of specific inhibitors for other related kinases such as MRCK. Here, we report the identification of chelerythrine chloride as a specific MRCK inhibitor. Its ability to block cellular activity of MRCK resulted in the specific loss of NM II-associated MLC phosphorylation in the lamella, and the consequential suppression of cell migration.
Copyright © 2011. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21457715     DOI: 10.1016/j.febslet.2011.03.054

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  21 in total

1.  Molecular pathways: targeting the kinase effectors of RHO-family GTPases.

Authors:  Tatiana Y Prudnikova; Sonali J Rawat; Jonathan Chernoff
Journal:  Clin Cancer Res       Date:  2014-10-21       Impact factor: 12.531

Review 2.  Myotonic dystrophy kinase-related Cdc42-binding kinases (MRCK), the ROCK-like effectors of Cdc42 and Rac1.

Authors:  Zhuoshen Zhao; Ed Manser
Journal:  Small GTPases       Date:  2015-06-19

Review 3.  Approaches of targeting Rho GTPases in cancer drug discovery.

Authors:  Yuan Lin; Yi Zheng
Journal:  Expert Opin Drug Discov       Date:  2015-06-18       Impact factor: 6.098

4.  Adaptor protein LRAP25 mediates myotonic dystrophy kinase-related Cdc42-binding kinase (MRCK) regulation of LIMK1 protein in lamellipodial F-actin dynamics.

Authors:  Irene Cheng Jie Lee; Thomas Leung; Ivan Tan
Journal:  J Biol Chem       Date:  2014-08-08       Impact factor: 5.157

5.  CIT, a gene involved in neurogenic cytokinesis, is mutated in human primary microcephaly.

Authors:  Sulman Basit; Khalid M Al-Harbi; Sabri A M Alhijji; Alia M Albalawi; Essa Alharby; Amr Eldardear; Mohammed I Samman
Journal:  Hum Genet       Date:  2016-08-12       Impact factor: 4.132

6.  Proteomic analysis identifies the E3 ubiquitin ligase Pdzrn3 as a regulatory target of Wnt5a-Ror signaling.

Authors:  Sara E Konopelski Snavely; Michael W Susman; Ryan C Kunz; Jia Tan; Srisathya Srinivasan; Michael D Cohen; Kyoko Okada; Helen Lamb; Shannon S Choi; Edith P Karuna; Michael K Scales; Steven P Gygi; Michael Eldon Greenberg; Hsin-Yi Henry Ho
Journal:  Proc Natl Acad Sci U S A       Date:  2021-06-22       Impact factor: 11.205

7.  Phosphorylation of Nonmuscle myosin II-A regulatory light chain resists Sendai virus fusion with host cells.

Authors:  Provas Das; Shekhar Saha; Sunandini Chandra; Alakesh Das; Sumit K Dey; Mahua R Das; Shamik Sen; Debi P Sarkar; Siddhartha S Jana
Journal:  Sci Rep       Date:  2015-05-20       Impact factor: 4.379

8.  Rap1 potentiates endothelial cell junctions by spatially controlling myosin II activity and actin organization.

Authors:  Koji Ando; Shigetomo Fukuhara; Takahiro Moriya; Yutaro Obara; Norimichi Nakahata; Naoki Mochizuki
Journal:  J Cell Biol       Date:  2013-09-09       Impact factor: 10.539

9.  Discovery of Potent and Selective MRCK Inhibitors with Therapeutic Effect on Skin Cancer.

Authors:  Mathieu Unbekandt; Simone Belshaw; Justin Bower; Maeve Clarke; Jacqueline Cordes; Diane Crighton; Daniel R Croft; Martin J Drysdale; Mathew J Garnett; Kathryn Gill; Christopher Gray; David A Greenhalgh; James A M Hall; Jennifer Konczal; Sergio Lilla; Duncan McArthur; Patricia McConnell; Laura McDonald; Lynn McGarry; Heather McKinnon; Carol McMenemy; Mokdad Mezna; Nicolas A Morrice; June Munro; Gregory Naylor; Nicola Rath; Alexander W Schüttelkopf; Mairi Sime; Michael F Olson
Journal:  Cancer Res       Date:  2018-01-30       Impact factor: 12.701

10.  E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer.

Authors:  Ilirjana Bajrami; Rebecca Marlow; Marieke van de Ven; Rachel Brough; Helen N Pemberton; Jessica Frankum; Feifei Song; Rumana Rafiq; Asha Konde; Dragomir B Krastev; Malini Menon; James Campbell; Aditi Gulati; Rahul Kumar; Stephen J Pettitt; Mark D Gurden; Marta Llorca Cardenosa; Irene Chong; Patrycja Gazinska; Fredrik Wallberg; Elinor J Sawyer; Lesley-Ann Martin; Mitch Dowsett; Spiros Linardopoulos; Rachael Natrajan; Colm J Ryan; Patrick W B Derksen; Jos Jonkers; Andrew N J Tutt; Alan Ashworth; Christopher J Lord
Journal:  Cancer Discov       Date:  2018-04       Impact factor: 39.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.